-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the ASCO journal "Journal of Clinical Oncology" (Journal of Clinical Oncology) published the 5-year follow-up results of KEYNOTE-024.
The research team pointed out in the paper that this is the first 5-year follow-up data of a Phase 3 trial of immunotherapy for the first-line treatment of NSCLC.
The KEYNOTE-024 trial was carried out in patients with metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS (tumor proportion score) ≥50% and no EGFR or ALK mutations, comparing pembrolizumab and platinum-containing chemotherapy as the first-line The effect of treatment.
In the survival data of this key report, in addition to the doubling of the median overall survival and the 5-year overall survival rate, the paper specifically pointed out that although two-thirds (99 cases/151 cases) of the chemotherapy group eventually crossed the group Received immunotherapy, but pembrolizumab still showed a significant survival benefit.
One of the authors of the study, Dr.
▲Survival curve (A) and progression-free survival curve (B) of pembrolizumab group and chemotherapy group (picture source: reference [1])
Pembrolizumab is also more advantageous in multiple other endpoints.
After considering the second-line treatment, pembrolizumab still has significant benefits, the median PFS2 (progress or death after randomization to second-line treatment) is longer (24.
In addition, the objective response rate assessed by the investigator in the pembrolizumab group was higher (46.
In the longer-term follow-up, the research team did not observe new safety signals.
The paper concluded that in the first-line treatment of 50% of PD-L1 metastatic NSCLC, pembrolizumab provides long-lasting and clinically significant long-term survival benefits compared to chemotherapy, and has become the standard treatment for these patients .
Dr.
Reference
[1] Martin Reck, et al.
[2] Lung Cancer Survival Continues to Rise With Immunotherap.
